MRSA pneumonia: Better outcome through continuous infusion of vancomycin?

Critical Care Medicine

Volumn 33, Issue 9, 2005, Pages 2127-2128

  Blot, Stijn ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Intensive care unit; Methicillin resistant Staphylococcus aureus, mortality; Outcome; Vancomycin; Ventilator associated pneumonia

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL VIRULENCE; CONTINUOUS INFUSION; EDITORIAL; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL;

EID: 24944499018     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000178288.70057.47     Document Type: Editorial

References (15)

1. Blot SI, Vandewoude KH, Hoste EA, et al: Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-2235
2. Blot S, Vandewoude K: Early detection of systemic infection. Acta Clin Belg 2004; 59:20-23
3. Levine DP, Fromm BS, Reddy BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-680
4. Cruciani M, Gatti G, Lazzarini L, et al: Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-869
5. Rello J, Sole-Violan J, Sa-Borges M, et al: Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-1987
6. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903
7. Heyland DK, Cook DJ, Griffith L, et al: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159:1249-1256
8. Hyatt JM, McKinnon PS, Zimmer GS, et al: The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28:143-160
9. De Paepe P, Belpaire FM, Buylaert WA: Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41:1135-1151
10. Vuagnat A, Stern R, Lotthe A, et al: High dose vancomycin for osteomyelitis: Continuous vs. intermittent infusion. J Clin Pharm Ther 2004; 29:351-357
11. James JK, Palmer SM, Levine DP, et al: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob Agents Chemother 1996; 40:696-700
12. Byl B, Clevenbergh P, Jacobs F, et al: Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-66
13. Wysocki M, Delatour F, Faurisson F, et al: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-2467
14. Di Filippo A, De Gaudio AR, Novelli A, et al: Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy 1998; 44:63-68
15. Kollef MH, Rello J, Cammarata SK, et al: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394